老化疗法通过消除衰老的内皮细胞来增加复制能力
Hossein Abdeahad1, Denisse G Moreno2, Samuel I Bloom3
1Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, UT, USA.
像Talabostat和Navitoclax这样的老化剂清除衰老的内皮细胞,促进老化文化中的增殖. 塔拉布拉斯塔通过减少氧化应激和改善这些衰老细胞中的基因组完整性,显示出更大的有效性.
科学领域:
- 老年学是一门学科.
- 心血管生物学 心血管生物学
- 细胞生物学 细胞生物学
背景情况:
- 衰老是心血管疾病 (CVD) 的主要危险因素,其主要特征是炎症,氧化应激和细胞衰老.
- 衰老的内皮细胞 (ECs) 导致血管功能障碍和心血管疾病的进展.
- 老化药物消除衰老细胞,但它们对老化的内皮细胞功能的影响尚未完全理解.
研究的目的:
- 调查老化药物Talabostat和Navitoclax对老化的内皮细胞培养物的作用.
- 评估老化治疗对内皮细胞增殖,衰老标志物,DNA损伤和端粒功能障碍的影响.
主要方法:
- 复制性衰老的人类静脉内皮细胞 (HUVEC) 用塔拉波斯塔特 (10μM) 或纳维托克拉克斯 (1.0μM) 治疗.
- 评估了衰老细胞负担,累积人口翻倍,端粒长度,DNA损伤标记 (53BP1),端粒功能障碍诱导的焦点 (TIF) 和线粒体活性氧物种 (mtROS).
主要成果:
- 塔拉波斯塔和纳维托克拉克斯都减少了衰老细胞负担,增加了内皮细胞的增殖.
- 塔拉波斯塔治疗减少了端粒长度,53BP1和TIFs,这表明与复制相关的端粒磨损.
- 纳维托克拉斯增加了mtROS,但没有改善DNA损伤或端粒功能障碍标记.
结论:
- 这两种老化剂都能降低老化的内皮细胞负担,并增强老化文化中的增殖.
- 塔拉波斯塔特表现出卓越的疗效,与减少氧化应激和改善基因组完整性有关.
- 这些发现突显了老化内皮细胞上老化疗法的差异性影响,为心血管疾病治疗策略提供了洞察力.
更多相关视频
08:56Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
Published on: July 12, 2022
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
相关概念视频
Replicative Cell Senescence
Replication in Eukaryotes
Many Proteins Orchestrate Replication at the Origin
Eukaryotic replication follows many of the same...
Replication in Eukaryotes
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
